Sutro Biopharma (STRO) Interest Coverage Ratio (2017 - 2022)
Sutro Biopharma (STRO) posted Interest Coverage Ratio of 5.36 for Q4 2025, up 317.94% sequentially from 2.46 in Q3 2025, and up 102.03% YoY from 2.65 in Q4 2024.
Powered by 
Analysis
Sutro Biopharma (STRO) Interest Coverage Ratio (2017 - 2022) Analysis & Trends
Sutro Biopharma has reported Interest Coverage Ratio for 9 years, with the latest figure at 5.36 in Q4 2025.
- Quarterly Interest Coverage Ratio rose 102.03% year-over-year to 5.36 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 70.29 (down 49.09% YoY) and the FY2025 annual result came in at 0.58, up 44.41% from the prior year.
- Interest Coverage Ratio climbed to 5.36 in Q4 2025 per STRO's latest filing, from 2.46 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 5.36 in Q4 2025 and troughed at 264.2 in Q4 2024.
- A 5-year average of 37.8 and a median of 9.48 in 2021 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2022 and 2025: Interest Coverage Ratio sank 11254.32% in 2022, then jumped 102.03% in 2025.
- Over 5 years, Interest Coverage Ratio stood at 9.53 in 2021, then sank by 1109.13% to 115.27 in 2022, then jumped by 91.82% to 9.43 in 2023, then plunged by 2700.48% to 264.2 in 2024, then surged by 102.03% to 5.36 in 2025.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 5.36, 2.46, and 0.15 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | -21.24 |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | 1.42 |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -0.08 |
| 10 | Sutro Biopharma | 332.59 Mn | 168.25 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | -7.61 |
| Jun 30, 2022 | -32.62 |
| Mar 31, 2022 | -59.56 |
| Dec 31, 2021 | -57.25 |
| Sep 30, 2021 | -42.29 |
| Jun 30, 2021 | -11.58 |
| Mar 31, 2021 | -22.16 |
| Dec 31, 2020 | 11.04 |
| Sep 30, 2020 | -4.58 |
| Jun 30, 2020 | -5.56 |
| Mar 31, 2020 | -18.16 |
| Dec 31, 2019 | -18.09 |
| Sep 30, 2019 | -11.16 |
| Jun 30, 2019 | -11.11 |
| Mar 31, 2019 | -12.30 |
| Dec 31, 2018 | 5.05 |
| Sep 30, 2018 | -21.03 |
| Jun 30, 2018 | 23.84 |
| Mar 31, 2018 | -30.56 |
| Dec 31, 2017 | -40.23 |